Published in Pharma Investments, Ventures and Law Weekly, November 20th, 2005
Research and development expenses for the third quarter increased to $20.5 million, compared to $16.6 million for the comparable quarter in 2004. For the 9-month period ended September 30, 2005, research and development expenses increased to $56.0 million, compared to $44.5 million for the same period in 2004.
The increase in research and development spending in both periods resulted from higher clinical trial expenditures associated with the company's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly